An interventional study of L-Carnitine Group in Infertility (IVF Patients), sponsored by The Obstetrics and Gynaecology Clinic Narodni Front. Recruiting at 1 site in Serbia. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by The Obstetrics and Gynaecology Clinic Narodni Front · Not applicable, Interventional, and Basic science
The goal of this clinical trial is to learn whether supplementation with L-carnitine improves outcomes in women undergoing in vitro fertilization (IVF). It will also evaluate the effect of supplementation on oocyte quality, embryo quality, and pregnancy rates. The main questions it aims to answer are:
Researchers will compare women receiving supplementation with women not receiving supplementation to determine whether the supplements improve IVF outcomes.
Participants will:
2,085 studies on the registry are indexed under Infertility; 357 are open to participants now.
This study's planned enrollment of 70 is below the median of 135 across 1,412 interventional studies indexed under Infertility.
Browse Infertility studies →This is the only study on the registry with The Obstetrics and Gynaecology Clinic Narodni Front as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive oral L-carnitine supplementation at a dose of 500 mg daily (once daily, powder dissolved in water, orally) starting 12 weeks before the day of oocyte retrieval.
Dietary Supplement: L-Carnitine Group
Participants who have not used carnitin supplementation.
A supplementation group will receive L-carnitine (500 mg) daily for 12 weeks before oocyte retrieval.
The impact of carnitine supplementation on the number of oocytes retrieved during in vitro fertilization and on IVF outcomes.
Assessment of the total count of oocytes retrieved per patient during transvaginal ultrasound-guided oocyte retrieval following controlled ovarian stimulation. Unit of measure: number of oocytes /count/ Measurement tool: inverted light microscope
Time frame: 3 months
The impact of carnitine supplementation on the number of good quality oocytes (metaphase II (MII) oocytes) retrieved during oocyte pick-up
Good quality oocytes (metaphase II oocytes) will be identified according to standard ESHRE consensus morphological criteria (evaluating polar body presence, cytoplasm texture, and zona pellucida integrity) using inverted light microscope as measurement tool, following denudation in cases of intracytoplasmatic sperm injection (ICSI) or Metaphase II (MII) oocytes will be identified based on successful fertilization (presence of two pronuclei, 2PN) using inverted light microscope following insemination as part of the IVF procedure. Unit of measure: number of metaphase II (MII) oocytes /count/ Measurement tool: inverted light microscope
Time frame: 3 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2026 to primary completion in Sep 2026, 3 months.
Of 385 non-industry interventional studies with no phase under Infertility, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 3 months is below that.
Counting every sponsor, half of 416 studies reached it within 24 months; a quarter within 10 and three quarters within 43.
Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Oct 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Carnitine